Autologous Hematopoietic Stem Cell Transplantation for Refractory Lymphomatoid Granulomatosis

Lemieux, Julie; Bernier, Vincent; Martel, Nadine; Delage, Robert

doi:10.1080/1024533021000053407

Cited by 19 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids followed by combination chemotherapy is most commonly recommended for the treatment of LYG, and experimental agents such as interferon alfa-2b, monoclonal antibodies to CD-20 (present on the surface of B cells), 52,53 and autologous hematopoietic stem cell transplantation have been proposed for resistant disease. 1,7,52,54 In PTLD, reduction in immunosuppressive therapy is generally recommended on diagnosis, yielding a remission rate of up to 50%. 9,55-57 Many other therapies have also been used, such as monoclonal anti-B-cell antibodies, 58-62 bexarotene, 63 chemotherapy, radiation therapy, donor lymphocyte transfusion, interferon therapy, antiviral medications, and intravenous immunoglobulin.…”

Section: Discussionmentioning

confidence: 99%

Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient

Kwon

Katz²,

Seykora³

et al. 2006

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient

Kwon

Katz²,

Seykora³

et al. 2006

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…These patients appear to be in a very poor prognostic group. There is 1 report in the literature of an autologous peripheral blood stem cell transplant in a patient with refractory LYG [9]. This patient manifested central nervous system progression during CHOP chemotherapy, after initially presenting with grade II/III disease in the lungs.…”

Section: Introductionmentioning

confidence: 87%

Prolonged remission of refractory lymphomatoid granulomatosisafter autologous hemopoietic stem cell transplantation with post-transplantation maintenance interferon

Johnston¹,

Coyle²,

Nevell

2006

Leukemia & Lymphoma

View full text Add to dashboard Cite

Lymphomatoid granulomatosis (LYG) is a rare Epstein Barr virus (EBV)-associated lymphoproliferative disease. Even with combination chemotherapy, mortality is high. There is no standard therapy for relapsed or refractory disease. There is only one report in the literature of a complete remission with high-dose chemotherapy and autologous stem cell transplantation. This study presents the case of a patient with progressive LYG, who was successfully treated with autologous stem cell transplantation after conditioning with high-dose chemotherapy and total body irradiation. After transplantation, maintenance therapy with interferon alpha 2a was administered for 3.75 years. The patient remains well and in remission 8 years post-transplantation. This is the first report of a durable (>1 year) complete remission after high-dose chemotherapy and autologous stem cell transplantation in LYG. The role of high-dose chemotherapy and autologous stem cell transplantation in relapsed or refractory cases merits further evaluation. The exact place of interferon in treatment of LYG remains to be clarified but is promising.

show abstract

“…Patients with grade I and II are treated with corticosteroids, while those with grade III are considered a subtype of diffuse large B cell lymphoma and treated clinically as such [8] . New therapeutic approaches such as rituximab, interferon-␣ 2b and autologous hematopoietic stem cell transplantation have been attempted [3,13] .…”

Section: Discussionmentioning

confidence: 99%

A Case of Pulmonary Lymphomatoid Granulomatosis Successfully Treated by Combination Chemotherapy with Rituximab

Jung

Sung²,

Lee³

et al. 2009

Chemotherapy

View full text Add to dashboard Cite

Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive lymphoproliferative disease characterized by Epstein-Barr virus-positive B cells admixed with reactive T cells. LYG most commonly affects the lung but can also involve other extrapulmonary sites. Pulmonary LYG usually presents as multiple pulmonary nodules with rapid progression and excavation. It can mimic various infectious diseases, vasculitis or metastatic malignancy and is difficult to be diagnosed clinically. Standard treatment for LYG has not yet been established. Despite combination chemotherapy, the overall prognosis is poor. Recently, anti-CD20 monoclonal antibody, rituximab, has been used to treat LYG. We report the case of a 70-year-old male patient with pulmonary LYG, who showed rapid remission of the disease after combination chemotherapy with rituximab.

show abstract

Autologous Hematopoietic Stem Cell Transplantation for Refractory Lymphomatoid Granulomatosis

Cited by 19 publications

References 9 publications

Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient

Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient

Prolonged remission of refractory lymphomatoid granulomatosisafter autologous hemopoietic stem cell transplantation with post-transplantation maintenance interferon

A Case of Pulmonary Lymphomatoid Granulomatosis Successfully Treated by Combination Chemotherapy with Rituximab

Contact Info

Product

Resources

About